Literature DB >> 28126330

First-line treatment options for ALK-rearranged lung cancer.

Benjamin Solomon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28126330     DOI： 10.1016/S0140-6736(17)30124-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets.

Authors:  Mercedes L Dalurzo; Alejandro Avilés-Salas; Fernando Augusto Soares; Yingyong Hou; Yuan Li; Anna Stroganova; Büge Öz; Arif Abdillah; Hui Wan; Yoon-La Choi
Journal:  Onco Targets Ther       Date:  2021-09-01       Impact factor: 4.345

2.  A novel EGFR-TKI inhibitor (cAMP-H3BO3complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes.

Authors:  Yongpeng Tong; Chunliu Huang; Junfang Zhang
Journal:  Oncotarget       Date:  2017-05-05

3.  Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis.

Authors:  Nicolas Girard; Delphine Cozzone; Lucie de Leotoing; Charlène Tournier; Alexandre Vainchtock; Bertrand Tehard; Alexis B Cortot
Journal:  ESMO Open       Date:  2018-09-08

4.  Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.

Authors:  Hao-Chuan Ma; Yi-Hong Liu; Kai-Lin Ding; Yu-Feng Liu; Wen-Jie Zhao; Yan-Juan Zhu; Xue-Song Chang; Ya-Dong Chen; Zhen-Zhen Xiao; Ya-Ya Yu; Rui Zhou; Hai-Bo Zhang
Journal:  BMC Cancer       Date:  2021-11-26       Impact factor: 4.430

Review 5.  The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.

Authors:  Valeria Cognigni; Federica Pecci; Alessio Lupi; Giada Pinterpe; Chiara De Filippis; Cristiano Felicetti; Luca Cantini; Rossana Berardi
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

6.  Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.

Authors:  Dae Ho Lee; Ming-Sound Tsao; Karl-Otto Kambartel; Hiroshi Isobe; Ming-Shyan Huang; Carlos H Barrios; Adnan Khattak; Filippo de Marinis; Smita Kothari; Ashwini Arunachalam; Xiting Cao; Thomas Burke; Amparo Valladares; Javier de Castro
Journal:  PLoS One       Date:  2018-08-27       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.